Windtree To Present at the ThinkEquity Conference on October 30th
Windtree Therapeutics (NasdaqCM: WINT), a biotechnology company focusing on innovative therapies for critical conditions, has announced its participation in the ThinkEquity Conference on October 30th. Craig Fraser, Chairman and CEO, will present a corporate update at 12:30pm ET and participate in one-on-one meetings with investors.
The presentation will cover:
- Recent positive topline data results from the Phase 2b SEISMiC Extension Study
- Updates on the company's lead drug candidate, istaroxime, for heart failure associated early cardiogenic shock
- Company strategy and planned milestones
This event provides an opportunity for Windtree to showcase its progress in developing therapies for critical conditions and diseases to potential investors and industry professionals.
Windtree Therapeutics (NasdaqCM: WINT), una società biotecnologica focalizzata su terapie innovative per condizioni critiche, ha annunciato la sua partecipazione alla ThinkEquity Conference il 30 ottobre. Craig Fraser, Presidente e CEO, presenterà un aggiornamento aziendale alle 12:30 ET e parteciperà a incontri one-to-one con gli investitori.
La presentazione coprirà:
- Recenti risultati positivi dei dati top-line dallo Studio di Estensione SEISMiC Fase 2b
- Aggiornamenti sul candidato principale della società, istaroxime, per l'insufficienza cardiaca associata a shock cardiogeno precoce
- Strategia dell'azienda e traguardi pianificati
Questo evento offre a Windtree l'opportunità di mostrare i suoi progressi nello sviluppo di terapie per condizioni critiche e malattie a potenziali investitori e professionisti del settore.
Windtree Therapeutics (NasdaqCM: WINT), una compañía de biotecnología enfocada en terapias innovadoras para condiciones críticas, ha anunciado su participación en la ThinkEquity Conference el 30 de octubre. Craig Fraser, Presidente y CEO, presentará una actualización corporativa a las 12:30 p.m. ET y participará en reuniones individuales con inversionistas.
La presentación cubrirá:
- Resultados de datos positivos recientes de la Extensión del Estudio SEISMiC Fase 2b
- Actualizaciones sobre el principal candidato de medicamentos de la compañía, istaroxime, para la insuficiencia cardíaca asociada con shock cardiogénico temprano
- Estrategia de la compañía y hitos planificados
Este evento brinda a Windtree la oportunidad de mostrar sus avances en el desarrollo de terapias para condiciones críticas y enfermedades a posibles inversionistas y profesionales de la industria.
Windtree Therapeutics (NasdaqCM: WINT), 심각한 질병에 대한 혁신적인 치료법에 집중하는 바이오테크 기업이 10월 30일에 열리는 ThinkEquity Conference에 참가한다고 발표했습니다. Craig Fraser, 회장 겸 CEO는 동부 표준시(ET) 오후 12시 30분에 기업 업데이트를 발표하고 투자자와 개별 회의를 가질 예정입니다.
발표 내용은 다음과 같습니다:
- 2b 단계 SEISMiC 연장 연구에서의 최근 긍정적인 주요 데이터 결과
- 조기 심장 쇼크와 관련된 심부전 치료를 위한 회사의 주요 약물 후보인 istaroxime에 대한 업데이트
- 회사의 전략 및 계획된 이정표
이 행사는 Windtree가 심각한 조건과 질병에 대한 치료법 개발에서의 진전을 잠재적 투자자와 산업 전문가에게 보여줄 수 있는 기회를 제공합니다.
Windtree Therapeutics (NasdaqCM: WINT), une entreprise biopharmaceutique axée sur des thérapies innovantes pour des conditions critiques, a annoncé sa participation à la ThinkEquity Conference le 30 octobre. Craig Fraser, Président et CEO, présentera une mise à jour de l'entreprise à 12h30 ET et participera à des réunions individuelles avec des investisseurs.
La présentation abordera :
- Des résultats de données top-line positifs récents de l'étude d'extension SEISMiC Phase 2b
- Des mises à jour sur le principal candidat de médicament de l'entreprise, istaroxime, pour l'insuffisance cardiaque associée à un choc cardiogénique précoce
- La stratégie de l'entreprise et les jalons prévus
Cet événement offre à Windtree l'opportunité de mettre en avant ses avancées dans le développement de thérapies pour des conditions critiques et des maladies devant des investisseurs potentiels et des professionnels de l'industrie.
Windtree Therapeutics (NasdaqCM: WINT), ein Biotechnologieunternehmen, das sich auf innovative Therapien für kritische Erkrankungen konzentriert, hat seine Teilnahme an der ThinkEquity Conference am 30. Oktober angekündigt. Craig Fraser, Vorsitzender und CEO, wird um 12:30 Uhr ET ein Unternehmensupdate präsentieren und an Einzelgesprächen mit Investoren teilnehmen.
Die Präsentation wird folgende Themen behandeln:
- Aktuelle positive Ergebnisse der Phase 2b SEISMiC Erweiterungsstudie
- Aktualisierungen zum Hauptmedikament des Unternehmens, istaroxime, für Herzinsuffizienz, die mit frühem kardiogenem Schock assoziiert ist
- Unternehmensstrategie und geplante Meilensteine
Diese Veranstaltung bietet Windtree die Gelegenheit, seine Fortschritte bei der Entwicklung von Therapien für kritische Erkrankungen und Krankheiten potenziellen Investoren und Fachleuten der Branche zu präsentieren.
- None.
- None.
WARRINGTON, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser, Chairman and Chief Executive Officer, will be presenting a corporate update at the ThinkEquity Conference on Oct 30th at 12:30pm ET. Windtree management will also be participating in 1x1 meetings with investors at the event.
Mr. Fraser will discuss the recent positive topline data results from its Phase 2b SEISMiC Extension Study from its lead drug candidate, istaroxime, in heart failure associated early cardiogenic shock as well as company strategy and planned milestones.
About Istaroxime
Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is designed as a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure have demonstrated that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.
Forward Looking Statements
This press release contains statements related to the potential clinical effects of istaroxime; the potential benefits and safety of istaroxime; the clinical development of istaroxime; and our research and development program for treating patients in early cardiogenic shock due to heart failure. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company’s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in Israel and Gaza, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
ecurtis@windtreetx.com
FAQ
When is Windtree Therapeutics (WINT) presenting at the ThinkEquity Conference?
What will Windtree Therapeutics (WINT) discuss in their presentation at the ThinkEquity Conference?
Who will be presenting for Windtree Therapeutics (WINT) at the ThinkEquity Conference?
What is the focus of Windtree Therapeutics' (WINT) lead drug candidate istaroxime?
